Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||BRAF V600E|
|Therapy||Ruxolitinib + Vemurafenib|
|Indication/Tumor Type||hairy cell leukemia|
|Response Type||predicted - sensitive|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF V600E||hairy cell leukemia||predicted - sensitive||Ruxolitinib + Vemurafenib||Phase II||Actionable||In a Phase II trial (HCL-PG03), combined Zelboraf (vemurafenib) and Jakafi (ruxolitinib) therapy in relapsed or refractory hairy cell leukemia patients with BRAF V600E demonstrated safety, and led to complete response (CR) in 87% (26/30) of patients, including 17 (65%) with negative minimal residual disease, a progression-free survival rate of 78% at a median follow-up of 37 months, and a relapse-free survival rate of 85% in the 26 patients with a CR at a median follow-up of 34 months (PMID: 33979489).||33979489|
|PubMed Id||Reference Title||Details|
|(33979489)||Vemurafenib plus Rituximab in Refractory or Relapsed Hairy-Cell Leukemia.||Full reference...|